Table 3.
Proportion of hypermucoviscosity (HV) phenotype among rmpA-positive K. pneumoniae isolates with and without ESBLs from (implying expression rate or normal function of rmpA)
| rmpA-positive Isolates (n) | HV-positive | HV-negative | p |
|---|---|---|---|
| 2004 – 2005 (111) | n = 95 | n = 16 | p for HV between 2004–2005 isolates |
| ESBL-KP (12) | 4 (33.3%) | 8 (66.7%) | < 0.0001* (vs. non-ESBL KP) |
| Sputum (6) | 1 (16.7%) | 5 | 0.546 (vs. non-sputum ESBL-KP) |
| Urine (2) | 0 | 2 | 0.515 (vs. non-urine ESBL-KP) |
| Blood (4) | 3 (75.0%) | 1 | 0.067 (vs. non-blood ESBL-KP) |
| Non-ESBL KP (99) | 91 (91.9%) | 8 (8.1%) | |
| Sputum (65) | 62 (95.4%) | 3 | < 0.0001* (vs. sputum ESBL-KP) |
| Blood (23) | 22 (95.7%) | 1 | 0.279 (vs. blood ESBL-KP) |
| Urine (4) | 1 (25.0%) | 3 | 1.000 (vs. urine ESBL-KP) 0.005*(vs blood non-ESBL KP) 0.002*(vs sputum non-ESBL KP) |
| Abscess pus (5) | 4 (80.0%) | 1 | 0.522 (vs. other non-ESBL KP) |
| Othersa (2) | 2 (100%) | 0 | |
| 2007 - 2010 | p for HV (vs. 2004–2005 isolates) | ||
| Blood ESBL-KP (49) | 26 (53.1%) | 23 (46.9%) | 0.054 (vs. non-blood ESBL-KP) |
| 0.617 (vs. blood ESBL-KP) | |||
| < 0.0001*(vs. non-ESBL KP) | |||
| 0.0003* (vs. blood non-ESBL KP) | |||
| 2010 | p for HV (vs. 2007–2010 isolates) | ||
| Blood non-ESBL BP (29) | 25 (86.2%) | 4 (13.8%) | 0.003* (vs. blood ESBL-KP) |
| P for HV (vs. 2004–2005 isolates) | |||
| 0.368 (vs. blood non-ESBL KP) | |||
| 2003–2004 (from 2 medical centers)b | p for HV (vs. 2007–2010 isolates) | ||
| Blood community-acquired KP (59)b | 51 (86.4%) | 8 (13.6%) | 0.0001* (vs. blood ESBL-KP) |
| p for HV (vs. 2004–2005 isolates) | |||
| 0.231 (vs. blood non-ESBL KP) |
a:
bile (n = 1) and pericardial effusion (n = 1).
b:
data extracted from reference 1 (Yu 2006) for external validation; the community-acquired KP isolates were almost non-ESBL KP (personal opinion).
*
p < 0.05.